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Abstract: Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that 
has several regulatory functions to help the body maintain normal volume status and electrolyte 
balance. Studies have shown significantly higher levels of aldosterone secretion in patients with 
congestive heart failure compared with normal patients. Elevated levels of aldosterone have 
been shown to elevate blood pressure, cause left ventricular hypertrophy, and promote cardiac 
fibrosis. An appreciation of the true role of aldosterone in patients with chronic heart failure did 
not become apparent until the publication of the Randomized Aldactone Evaluation Study. Until 
recently, the use of aldosterone receptor antagonists has been limited to patients with severe 
heart failure and patients with heart failure following myocardial infarction. The Eplerenone 
in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study 
added additional evidence to support the expanded use of aldosterone receptor antagonists in 
heart failure patients. The results of the EMPHASIS-HF trial showed that patients with mild-
  to-moderate (New York Heart Association Class II) heart failure had reductions in mortality and 
hospitalizations from the addition of eplerenone to optimal medical therapy. Evidence remains 
elusive about the exact mechanism by which aldosterone receptor antagonists improve heart 
failure morbidity and mortality. The benefits of aldosterone receptor antagonist use in heart 
failure must be weighed against the potential risk of complications, ie, hyperkalemia and, in 
the case of spironolactone, possible endocrine abnormalities, in particular gynecomastia. With 
appropriate monitoring, these risks can be minimized. We now have evidence that patients with 
mild-to-severe symptoms associated with systolic heart failure will benefit from the addition of 
an aldosterone receptor antagonist to the standard therapies of angiotensin-converting enzyme 
inhibitors and beta-blockers. This review will address the pharmacologic basis of aldosterone 
receptor antagonists in patients with heart failure and the clinical impact of this therapy.
Keywords: aldosterone receptor antagonists, eplerenone, spironolactone, systolic heart 
failure
Introduction
Heart failure is a common disorder, particularly among the elderly. It carries a heavy 
financial burden due to frequent hospitalizations. Pharmacologic therapy, including 
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-
blockers are the cornerstone of therapy for the vast majority of patients. Diuretics 
are indicated for patients with signs or symptoms of congestion and digoxin is used 
for those patients remaining symptomatic despite optimal therapy with angiotensin-
  converting enzyme inhibitors and beta-blockers. Spironolactone, an aldosterone 
receptor antagonist, has been used for decades in the management of excess volume, 
although generally playing a minor role relative to the more potent loop diuretics. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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However, an appreciation of the true role of aldosterone in 
patients with chronic heart failure did not become apparent 
until the publication of the Randomized Aldactone Evaluation 
Study (RALES).1 This review will address the pharmacologic 
basis of aldosterone receptor antagonists in patients with 
heart failure and the clinical impact of this therapy.
Overview of aldosterone
Aldosterone and the kidney
Aldosterone is a mineralocorticoid hormone synthesized by 
the adrenal glands that has several regulatory functions to 
help the body maintain normal volume status and electrolyte 
balance. Aldosterone secretion is controlled in part by angio-
tensin II and potassium levels.2,3 However, adrenocorticotro-
pic hormone, hyponatremia, and atrial natriuretic peptide 
have also been described in the regulation of aldosterone.4 
The renin-angiotensin-aldosterone system controls the 
production of angiotensin II through sensing intravascular 
volume. Receptors within the afferent arterioles of the 
juxtaglomerular apparatus sense a decrease in intravascular 
volume, stimulating the release of renin.5 This causes the con-
version of angiotensinogen to angiotensin I, which is further 
cleaved to angiotensin II by angiotensin-converting enzyme. 
Angiotensin II has multiple effects in the body, including 
systemic vasoconstriction, cardiac remodeling, and sodium 
and water retention through aldosterone secretion.6
Aldosterone is synthesized in the zona glomerulosa 
after angiotensin II binds to a G protein coupled receptor, 
prompting the release of secondary messengers. This pro-
cess causes intracellular calcium concentrations to increase 
biosynthesis of aldosterone.2,7,8 Hyperkalemia has also 
been associated with aldosterone secretion.9 Studies by 
Himathongkam et al and Young et al provided evidence that 
as potassium levels rose above 3.5 mEq/L there was a linear 
increase in aldosterone levels.10,11 While the exact mecha-
nism of how potassium affects aldosterone levels remains 
elusive, there appears to be an association between elevated 
potassium and angiotensin II.12
Aldosterone works primarily to regulate the electrolyte 
balance as well as volume status through its effects on the 
distal tubules and collecting ducts of the kidneys by controlling 
sodium reabsorption and potassium excretion.9 Aldosterone 
enhances sodium reabsorption in the distal tubules by increas-
ing the number of Na+/Cl- cotransporters in the luminal 
membrane.13 Within the collecting ducts, aldosterone increases 
the amount of sodium and potassium that is filtered across 
the apical membrane through increasing transporter proteins. 
Ultimately, elevated aldosterone levels affect Na+/K+-ATPase 
by increasing its activity and abundance, promoting sodium 
reabsorption and potassium secretion.14,15 Thus the addition of 
an aldosterone receptor antagonist will help maintain adequate 
serum potassium concentrations.
Aldosterone and the cardiovascular 
system
Hypoperfusion causes release of renin and ultimately leads 
to increased aldosterone levels, which increase intravascular 
volume and preload. However, in heart failure, the problem 
of hypoperfusion is not related to a low volume status but to 
a decrease in stroke volume. The compensatory mechanism 
of the kidneys to increase intravascular volume increases 
the workload on an already failing heart. Studies have 
shown significantly higher levels of aldosterone secretion in 
patients with congestive heart failure compared with normal 
patients.16–18 While aldosterone has been shown to be an inte-
gral part of maintaining fluid and electrolyte balance, it is also 
known to cause damage to the cardiovascular system. Similar 
to angiotensin II, too much aldosterone can worsen certain 
conditions. Elevated levels of aldosterone have repeatedly 
been shown to elevate blood pressure, cause left ventricular 
hypertrophy, and promote cardiac fibrosis.19–22
Aldosterone synthase is mediated by angiotensin II. 
There are also mineralocorticoid receptors present in 
the heart and aldosterone is produced by the diseased 
myocardium. While the exact mechanism by which cardiac 
fibrosis is promoted remains controversial, several animal 
models suggest that an increase in angiotensin type 1 (AT1) 
receptors may play a role.23,24 Binding of angiotensin II will 
lead to higher secretion of aldosterone. The idea of the ability 
of angiotensin II to work in pathways that do not require AT1 
receptors stems from a study by Viridis et al.25 They were able 
to demonstrate in rats that structural and functional damage 
caused by angiotensin II was partially corrected with the 
use of spironolactone. Harda et al demonstrated that aldos-
terone causes an upregulation of angiotensin-converting 
enzyme mRNA expression, leading to increased levels of 
angiotensin II.26 The initiation of this process leads to a situa-
tion that feeds itself. Angiotensin II will cause an increase in 
the circulating aldosterone, which produces upregulation of 
angiotensin-converting enzyme activity, leading to increased 
levels of angiotensin II.25,27 Several investigators have looked 
at the interaction between angiotensin II and aldosterone 
in vascular smooth muscle animal models. Based on their 
findings, there is a possibility that synergism exists between 
angiotensin II and aldosterone, as well as an interaction 
between mineralocorticoid receptors and AT1 receptors.28–30 Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The first report that nonrenal effects of aldosterone existed 
was in animal models which showed the action of aldoster-
one to occur within minutes, now termed “nongenomic”.31 
Chai et al were the first to demonstrate nongenomic actions 
of aldosterone in the human heart.31 These findings were 
followed by studies showing that aldosterone had deleteri-
ous effects on contractility and metabolic functions of the 
ischemic heart, increased systemic vascular resistance, and 
increased the vasoconstrictive action of angiotensin II in the 
coronary arteries.32–34
Another mechanism for the elevated aldosterone concen-
trations seen in heart failure relates to decreased metabolic 
clearance by the liver. Due to the hypoperfusion seen with 
a failing heart, aldosterone clearance is not complete within 
one passage through the liver, as occurs in normal subjects.35 
The inability to clear aldosterone properly can lead to 
  significantly higher aldosterone plasma concentrations.35,36 
There are also studies showing that the development of 
cardiovascular disease may be independent of angiotensin II, 
based on correlations between aldosterone and cardiovascular 
morbidity and mortality.37,38 Patients with excess aldosterone 
secretion due to primary aldosteronism have an increased 
cardiovascular risk compared with patients having primary 
hypertension.2,3,39
Aldosterone receptor antagonists
Aldosterone receptor antagonists compete with aldosterone to 
bind at the mineralocorticoid receptor. They were originally 
developed in an effort to counteract the effects of aldoster-
one, specifically aldosterone-related potassium excretion. 
Spironolactone was considered a potassium-sparing diuretic, 
but later studies have demonstrated nonrenal benefits. The 
location of the mineralocorticoid receptor (kidney, heart/
blood vessels) has an impact on the effect manifested through 
binding. Prior to the randomized trials looking at specific 
aldosterone receptor antagonists in heart failure, there were 
compelling data showing beneficial effects on preventing 
cardiac fibrosis in animal models.19,22,35
Currently, there are two aldosterone receptor antagonists 
that act at mineralocorticoid receptors, ie, spironolactone 
and eplerenone. Spironolactone and eplerenone are structur-
ally similar compounds devised to block aldosterone at the 
mineralocorticoid receptor. Spironolactone has structural 
elements similar to progesterone, resulting in progestogenic 
and antiandrogenic adverse effects.35 Eplerenone is a deriva-
tive of spironolactone and designed to avoid side effects that 
occur as a result of the interaction between spironolactone and 
testosterone and progesterone receptors.3 By substituting the 
17 α-thoacetyl group, eplerenone has increased selectivity for 
the aldosterone receptor over other steroid receptors.3 While 
in vitro studies have shown a significantly greater affinity 
for spironolactone at aldosterone receptors, eplerenone was 
seen to inhibit aldosterone binding at a much lower in vivo 
dosage.34
The pharmacokinetic profiles between the two drugs 
differ (see Table 1). Spironolactone has a shorter half-
life (t1/21.3–1.4 hours)40 and is metabolized to three active 
metabolites which prolong its activity (13.8–16.5 hours41 
and 17–22 hours42). The active metabolites of spironolactone 
are excreted by the kidney, so spironolactone requires close 
monitoring if given to patients with renal insufficiency. 
Eplerenone undergoes rapid metabolism by the liver to inac-
tive metabolites (t1/2 4–6 hours).43 Elimination occurs pre-
dominately through the kidneys for both agents (eplerenone 
67% and spironolactone 47%–51%); however, a higher per-
centage of spironolactone (35%–41%) is eliminated through 
the feces compared with eplerenone (32%).43–45
These elimination properties have an important role in 
determining appropriate doses for patients with renal and/or 
hepatic dysfunction. Extra caution needs to be exercised in 
patient with renal dysfunction because failure to eliminate 
the aldosterone receptor antagonist leads to accumulation 
of drug, causing increased serum potassium concentrations. 
Both the area under the curve (AUC) and peak plasma 
concentration (Cmax) of eplerenone are increased with renal 
insufficiency.3
In the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF), patients 
were given a lower dose (25 mg on alternative days) if 
they had a glomerular filtration rate ,30 mL/min/m2.46 
This reduction in dose was used to minimize the develop-
ment of hyperkalemia. It has been reported that both the 
AUC and Cmax of eplerenone are increased in the pres-
ence of renal insufficiency.2 Caution should initially be 
exercised in patients receiving both spironolactone and 
eplerenone when hepatic insufficiency is present. The AUC 
and Cmax of eplerenone were increased by 3.6% and 42%, 
respectively, when normal patients were compared with 
patients classified as having Child–Pugh Class B hepatic 
impairment.3 Accumulation was not seen with canrenone, 
a major metabolite of spironolactone in a study by Jackson 
et al.47 However, the elimination half-life was increased 
from the reported range of 13.5–24 hours to 50 hours 
(range 32–105 hours) in five patients with chronic liver 
disease, indicating a possible prolongation of the effect of 
spironolactone.47Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Adverse effects
One limitation of spironolactone use is associated with 
its action on androgen and progesterone receptors. Unlike 
eplerenone, which is more selective for mineralocorti-
coid receptors, spironolactone has both dose-dependent 
and duration-dependent sexual side effects that decreases 
tolerability.48 In RALES, spironolactone was associated with 
a 10% incidence of gynecomastia or mastodynia in men.1 
Additionally, when patients receive doses higher than those 
used in RALES there is an even higher rate (52.2% of patients 
with doses $150 mg) of development of gynecomastia.48,49 
In the Eplerenone Post-Acute Myocardial Infarction Heart 
Failure Efficacy and Survival Study (EPHESUS)50 and, more 
recently, the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF)46 studies, 
the incidence of gynecomastia and other breast disorders was 
similar between eplerenone and placebo.
The potential for developing hyperkalemia relates 
directly to the mechanism of action of either aldosterone 
receptor antagonist. Previous studies looking at aldosterone 
receptor antagonists in essential hypertension have noted a 
dose-related increase in serum potassium concentrations.49,51 
In RALES, the median increase in serum potassium due to 
spironolactone was 0.3 mmol/L when given with angiotensin-
converting enzyme inhibitors and loop diuretics.1 In the 
EPHESUS and EMPHASIS-HF trials, potassium levels 
increased from baseline by 0.3 mmol/L and 0.16 mmol/L, 
respectively.46,50 The effect of eplerenone on potassium lev-
els in the two trials was similar to the results published by 
Weinberger et al, who reported changes up to 0.36 mmol/L 
on doses of 400 mg/day.51
Efficacy of aldosterone blockade  
in heart failure patients
The deleterious effects of the renin-angiotensin-aldosterone 
system on the cardiovascular system, including left ventricular 
remodeling, vasoconstriction/hypertension, and ventricular 
hypertrophy have been known for many years. Aldosterone, 
as described earlier, has many effects on the cardiovascular 
system, and the benefits of adding an aldosterone receptor 
antagonist to a heart failure regimen are seen in the RALES, 
EPHESUS, and EMPHASIS-HF trials.1,46,50 While each trial 
was directed at a specific heart failure patient population, the 
results were similar in demonstrating overwhelming benefit 
with the addition of an aldosterone receptor antagonist to 
patients with heart failure. A comparison of the three trials 
can be seen in Table 2.
RALES was the first trial investigating the use of an aldos-
terone receptor antagonistin heart failure patients and was 
conducted in 1995–1998. The trial was designed to determine 
the effect of spironolactone on death from any cause (pri-
mary endpoint) in patients with New York Heart Association 
Class III/IV symptoms of heart failure. After the fifth interim 
analysis, the beneficial effect of spironolactone exceeded 
the predetermined “z-value” and the trial was stopped for 
complete analysis after a mean follow-up of 24 months.1 
A total of 1663 patients were enrolled. Data were analyzed 
using the intention-to-treat principle. The primary endpoint 
occurred in 284 patients receiving spironolactone and 386 
patients receiving placebo. Kaplan–Meier analysis estimated 
a relative risk of 0.70 (P , 0.001) in favor of spironolactone.1 
All of the secondary endpoints showed significant benefits 
in favor of spironolactone over placebo at final analysis.   
Table 1 Pharmacokinetic properties and clinical uses for spironolactone and eplerenone34,40,43,44
Spironolactone Eplerenone
Pharmacokinetic properties
Absorption 73% bioavailable (↑ by food) 69% bioavailable
Distribution 90% protein bound 50% protein bound
Metabolism Liver and kidney (active metabolites) Liver (3A4) (inactive metabolites)
excretion Renal (47%–51%) Renal (67%)
Feces (35%–41%) Feces (32%)
elimination half-life (t1/2) Parent compound: 1.3–1.4 hours 4–6 hours
Active metabolites: 13.8–22 hours
Clinical uses
Hypertension 50–100 mg/day (single or divided doses) adjust in 2 weeks 50 mg once or twice daily
Heart failure 25 mg/day increased to 50 mg/day after  
8 weeks (as tolerated)
25 mg/day increased to 50 mg/day after  
1 month (as tolerated)
Primary hyperaldosteronism 400 mg/day
edematous conditions associated with 
cirrhosis and nephrotic syndrome
100 mg/day (range 25–200 mg)
Hypokalemia 25–100 mg/dayVascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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A safety analysis revealed that 214 and 200 patients, in the 
spironolactone and placebo groups, respectively, dropped 
out of the study. Reasons for discontinuing were lack of 
response, adverse events, or for administrative reasons.1 
Serum creatinine increased by 0.05–0.1 mg/dL and potassium 
levels rose by 0.3 mmol/L compared with the placebo arm. 
There was a statistically significant difference between the 
spironolactone and placebo groups regarding the development 
of gynecomastia or breast pain (10% vs 1%) which may have 
contributed to the discontinuation rates with spironolactone 
when compared with placebo due to an adverse event (8% vs 
5%).1 Overall, RALES showed significant benefits of adding 
spironolactone to patients with moderate-to-severe symptoms 
of heart failure on what was considered optimal drug therapy 
(angiotensin-converting enzyme inhibitor/loop diuretic/
digoxin) at the time. However, only 10% of the patients in 
RALES were receiving a beta-blocker at baseline and there 
is no mention of the use of devices that may affect outcomes 
(implantable cardioverter defibrillators or cardiac resynchro-
nization therapy) or whether revascularization therapy was 
used in patients with ischemia.
RALES was followed by the EPHESUS and 
EMPHASIS-HF trials, which investigated eplerenone in two 
different heart failure patient populations. The EPHESUS trial 
was published in 2003 and investigated eplerenone 25 mg daily 
in a placebo-controlled, randomized, double-blind, event-
driven trial.50 Patients (6642 total analyzed) were included 
if they were status post (3–14 days) acute myocardial infarc-
tion complicated by left ventricular dysfunction, denoted 
by left ventricular ejection fraction #40%, and heart failure 
symptoms or diabetes with left ventricular dysfunction 
and no heart failure symptoms. Patients were receiving 
usual medical therapy for acute myocardial infarction 
complicated by left ventricular dysfunction, including 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers (86%), beta-blockers (75%), statins 
(47%), aspirin (89%), and diuretics (60%) at baseline. 
There were two primary endpoints, ie, time to death from 
any cause and time to death from cardiovascular causes or 
first hospitalization for a cardiovascular event. There were 
1012 deaths in the trial with eplerenone (14.4%) showing 
a significant benefit vs placebo (16.7%) in mortality (rela-
tive risk [RR]: 0.85; P = 0.008). The time to cardiovascular 
death or hospitalization related to a cardiovascular event 
also favored the patients receiving eplerenone (26.7%) 
compared with placebo (30.0%, RR: 0.87; P = 0.002).50 
Secondary endpoints included reduced death from cardio-
vascular causes (RR: 0.83; P = 0.005), which was primarily Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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due to the prevention of sudden   cardiac death (RR: 0.79; 
P = 0.03), and decreased hospitalization for cardiovascular 
events (RR:0.87; P = 0.03), largely   attributed to decreasing 
hospitalization for heart failure (RR: 0.77; P = 0.002) in the 
eplerenone group. A significantly higher percentage of patients 
were on beta-blockers in this trial compared with RALES (75% 
vs 11%).46,50 However, both trials showed a decrease in sud-
den cardiac death in patients receiving an aldosterone recep-
tor antagonist compared with placebo. While the Carvedilol 
Post-Infarct Survival Control in Left Ventricular Dysfunction 
(CAPRICORN) trial showed morbidity and mortality benefits 
of beta-blockade following an acute myocardial infarction,52 
the decrease in sudden cardiac death in the EPHESUS trial 
demonstrated an additive benefit of an aldosterone receptor 
antagonist in patients receiving beta-blockers.
Serious hyperkalemia (serum potassium .6 mmol/L) 
occurred more frequently with eplerenone (5.5%) than with 
placebo (3.9%), particularly in those patients with a baseline 
creatinine clearance of ,50 mL/min. Serious hypokalemia 
(serum potassium ,3.5 mmol/L) occurred more frequently 
with placebo (13.1%) than with eplerenone (8.4%).50 As 
opposed to RALES, which reported a significant increase 
in gynecomastia with spironolactone, the EPHESUS trial 
showed no difference between eplerenone and placebo in the 
development of gynecomastia, breast pain, or impotence.50 
Unlike RALES, 75% of patients in EPHESUS were receiving 
beta-blockers. However, as with RALES, there is no mention 
of the use of device or revascularization therapy. Although 
not specifically designed to look at smaller subgroups, it is 
interesting to note that in some subgroups, eplerenone did 
not demonstrate a mortality benefit; however the confidence 
intervals are wide, and it would be inappropriate to assume 
that these differences are meaningful. Although some 
improvement seen in the eplerenone group could be due to 
natural recovery following an acute myocardial infarction, it 
would be expected this would have also occurred in patients 
receiving placebo.
The second major trial involving eplerenone, 
EMPHASIS-HF, randomly assigned 2737 patients with 
mild-to-moderate heart failure (New York Heart Association 
Class II) with an ejection fraction #35% to either epler-
enone or placebo.46 Table 2 gives specific inclusion and 
exclusion criteria for the EMPHASIS-HF trial. The primary 
outcome was a composite of death from a cardiovascular 
cause or hospitalization for heart failure. After a follow-up 
period of 21 months, the primary endpoint was reached in 
18.3% of the patients receiving eplerenone vs 25.9% in the 
placebo group (hazards ratio 0.63; P , 0.001). Secondary 
endpoints, including all-cause mortality, cardiovascular 
mortality, hospitalization for heart failure, cardiovascular 
causes, or any reason, all showed benefits of eplerenone over 
placebo. In this trial, 13% of patients had an implantable 
cardioverter defibrillator, 2.2% had cardiac resynchroniza-
tion therapy, and 6.3% had both at baseline. In terms of 
adverse events, the EMPHASIS-HF trial had results that 
were similar to the EPHESUS trial. Hyperkalemia occurred 
more frequently in the eplerenone group (8%) when com-
pared with placebo (3.7%, P , 0.001). Hypokalemia was 
noted more often in patients receiving placebo (2.2%) vs 
eplerenone (1.2%). A limitation of the EMPHASIS-HF 
trial is the exclusion of a substantial number of patients 
with New York Heart Association Class II symptoms but 
an ejection fraction .30%.53
The RALES, EPHESUS, and EMPHASIS-HF trials have 
provided clear and consistent evidence that adding an aldos-
terone receptor antagonist to patients with various degrees of 
heart failure results in statistically and clinically significant 
beneficial effects. A direct comparison between the three 
trials is not appropriate because the drugs were evaluated in 
different patient populations. However, due to its selectivity 
for the mineralocorticoid receptor, eplerenone appears to 
offer a more favorable side effect profile when compared 
with spironolactone.
The most recent Heart Failure Society of America guide-
lines in 2010 recommend starting an aldosterone receptor 
antagonist in patients with New York Heart Association Class 
IV heart failure with reduced left ventricular ejection fraction 
(35%) and considering one in patients post-MI with signs 
of heart failure or a history of diabetes mellitus and a left 
ventricular ejection fraction ,40%.54 It is highly likely that 
the guidelines will be revised to expand the recommenda-
tion to patients with mild symptoms, given the results of the 
EMPHASIS-HF study.
The exact mechanism by which eplerenone improves 
morbidity and mortality is unclear. A major consideration 
for improved outcomes concerns the effect of the drug on the 
reversal of cardiac remodeling. While this was not specifically 
addressed in any of the aldosterone receptor antagonist trials, 
there are data showing an improvement in left ventricular 
ejection fraction of 3.1% when using an aldosterone receptor 
antagonist.55 The ability of aldosterone blockade to improve 
left ventricular ejection fraction was also seen in the Italian 
study known as AREA-IN-CHF (antiremodeling effect of 
canrenone in patients with mild chronic heart failure).56 In this 
trial, canrenone provided slightly more improvement in left 
ventricular ejection fraction in New York Heart   Association Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Class II heart failure compared with placebo. In contrast 
with these findings, the Reversal of Cardiac Remodeling 
with Eplerenone (REMODEL) trial, which had a similar 
study design to that of EMPHASIS-HF, showed no improve-
ment in left ventricular remodeling or function, or in qual-
ity of life.57 It is important to note that there were only 216 
patients with stable heart failure (left ventricular ejection 
fraction ,35% and New York Heart Association Class II/
III), on optimal therapy (96% on angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers and 95% 
on beta-blockers), and these patients were only observed 
for 36 weeks as opposed to the 21-month follow-up in the 
EMPHASIS-HF trial.
There are no studies that directly compare spironolac-
tone and eplerenone. Spironolactone has been available for 
decades, and usually costs less than eplerenone. Eplerenone 
is more selective for the mineralocorticoid receptor and, as 
such, adverse effects, eg, gynecomastia, occur less often. 
Testosterone may protect the heart from apoptosis and, as 
such, the protective effect of testosterone may be dimin-
ished with spironolactone as compared with eplerenone.58 
It is not known if the antiandrogen effect of spironolac-
tone has any effect on testicular or prostate cancer. The 
majority of patients in the major studies of aldosterone 
receptor antagonists (EPHESUS, EMPAHSIS-HF, and 
RALES) have been male Caucasians. Additional studies 
with more diverse patients and patients with heart failure 
and a preserved ejection fraction will provide additional 
needed data.
Hyperkalemia from the use of an aldosterone receptor 
antagonist can lead to serious adverse consequences, includ-
ing muscle weakness/paralysis, cardiac conduction abnormal-
ities, and cardiac arrhythmias. Electrocardiographic changes 
due to hyperkalemia initially present as peaked T waves with 
a shortened QT interval. As the serum potassium increases 
the PR interval and the QRS duration lengthens, the P wave 
may disappear and eventually the QRS develops into a sine 
wave. Electrocardiographic changes are more likely to occur 
with the rapid onset of hyperkalemia and in the presence of 
hypocalcemia, hyponatremia, and acidemia.59 It is essential 
to monitor serum potassium concentrations frequently in 
order to avoid potentially life-threatening adverse effects of 
aldosterone receptor antagonists.
Conclusion
Aldosterone is a mineralocorticoid produced in the 
adrenals, myocardium, brain, and blood vessels. The 
effects of   aldosterone on fluid and electrolyte balance 
  (renin-  angiotensin-aldosterone system) have been known 
for many years. Newer data support the concept that 
  aldosterone can have direct effects on the cardiovascular 
system. There is increased evidence suggesting syner-
gism between angiotensin II and aldosterone, making the 
addition of an aldosterone receptor antagonist to current 
optimal therapy (angiotensin-converting enzyme inhibitor/
angiotens in receptor blocker, diuretic, β-blocker) a strong 
consideration. The selective nature of eplerenone makes it 
an appealing choice when the use of an aldosterone receptor 
antagonist is warranted. Eplerenone has shown significant 
benefits for use in two specific heart failure patient popu-
lations, ie, acute myocardial infarction with symptoms of   
heart failure and reduced left ventricular ejection fraction 
(#30%–35%) and mild-to-moderate heart failure (New York 
Heart Association Class II). Overall, eplerenone confers 
reduced morbidity and mortality in patients with heart fail-
ure based on the EPHESUS and EMPHASIS-HF trials and 
should be strongly considered in all patients with symptoms 
of systolic dysfunction, and particularly in those who require 
potassium supplementation.
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